Xenograft tumours were subsequently established from BRCA2+/+ and BRCA2−/− HCT116 cells and assessed for their response to chlorambucil, cisplatin and talazoparib (Appendix Fig S6B). This evidence concerns the gene BRCA2 and neoplasm.